The Respiratory Drug Delivery Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Launch of Smart/Digital Inhalers and Outbreak of COVID-19 Pandemic Projected to Spur Industry Growth
At present, smart inhalers just record the patient’s actuation, which is a time and date stamp, during use. Numerous firms are producing devices that can be connected to inhalers that are currently in use. Leading the way in this trend are the American organisations Propeller Health and Adherium, both of which were founded in New Zealand. Data from clinical studies conducted by both firms indicate that patients might gain advantages from utilising their products. In another instance, Innovate UK provided co-funding to Aseptika, a firm that specialises in developing intelligent inhalers for patients with chronic respiratory conditions, in January 2023. With integrated 5G mobile connectivity, the company’s third-generation smart inhaler tracker will be developed further with the help of the Smart Award.
Since COVID-19 affects particular lung tissues, bronchodilators are frequently utilised as part of therapy. Nebulizers may encourage the creation of aerosolized virus in patients, which could worsen the spread of COVID-19. For this reason, the use of MDI is advised. There is a growing medical need for COVID-19 treatment, which is creating a shortage of inhalers. For instance, a strategic agreement was reached in October 2022 between GenScript ProBio and Hibiocy Co. Ltd. to accelerate the development of COVITRAP, a respiratory-care medical device that includes a human antibody for COVID-19. By preventing the COVID-19 virus from sticking to the nasal cavity’s interior surfaces, COVITRAP, a nasal spray, can reduce the amount of virus present in the nasal cavity. Following approval by the Thai FDA, COVITRAP was formally released onto the Thai market. This indicates that in reaction to the COVID-19 pandemic, there has been an increased demand for respiratory medicine delivery technologies to treat patients with the virus as well as those suffering from bronchitis, asthma, and other respiratory conditions.
Stringent Government Regulations Likely to Challenge Industry Growth
The FDA usually goes through lengthy and laborious processes to approve medical devices, drugs, and drug technology before a product can be sold. This usually poses a challenge to companies that conduct intensive R&D in order to launch new products on the market. Authorities rigorously verify the product’s safety and use before making it available for sale to the general public. As a drug-device combination of 97 items, MDIs and DPIs are mixed products subject to the current good manufacturing practice (CGMP) requirements for pharmaceuticals and devices. In particular, they apply to all MDIs and DPIs that have a device component that is subject to design controls (21 CFR 820.30). Industry guidelines on pharmaceutical development, which are founded on the concepts of quality via design, address the processes of product design and development. Even though quality via 110 design and design controls have the same features and objectives, the Quality System 111 Regulation (21 CFR 820) for devices provides design requirements.
What Questions Should You Ask Before Buying a Market Research Report?
- How is the respiratory drug delivery market evolving?
- What is driving and restraining the respiratory drug delivery market?
- How will each point of care diagnostic submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
- How will the market shares for each respiratory drug delivery submarket develop from 2024 to 2034?
- What will be the main driver for the overall market from 2024 to 2034?
- Will leading respiratory drug delivery markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
- Who are the leading players and what are their prospects over the forecast period?
- What are the respiratory drug delivery projects for these leading companies?
- How will the industry evolve during the period between 2024 and 2034? What are the implications of respiratory drug delivery projects taking place now and over the next 10 years?
- Is there a greater need for product commercialisation to further scale the respiratory drug delivery market?
- Where is the respiratory drug delivery market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the Respiratory Drug Delivery market today, and over the next 10 years:
- Our 348-page report provides 147 tables, 249 charts, and graphs exclusively to you.
- The report highlights key lucrative areas in the industry so you can target them – NOW.
- It contains in-depth analysis of global, regional and national sales and growth.
- It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the respiratory drug delivery market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2034 and other analyses reveal commercial prospects
- In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
- You will find original analyses, with business outlooks and developments.
- Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), impact of rising respiratory drug delivery prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.
Segments Covered in the Report
Product
Formulations
- Dry Powder
- Suspension Aerosol
- Solution Aerosol
Devices
- Metered Dose Inhalers (MDIs)
- Dry Powder Inhalers (DPIs)
- Nebulizers
- Accessories
Nebulizers
- Soft Mist Nebulizers
- Jet Nebulizers
- Ultrasonic Nebulizers
Canister
- Plain Canisters
- Coated Canister
Application
- Asthma
- COPD
- Cystic Fibrosis
- Others
End-users
- Homecare settings
- Hospitals & Clinics
- Other End-users
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 25 leading national markets:
North America
Europe
- Germany
- UK
- France
- Italy
- Spain
- Switzerland
- Russia
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
MEA
- GCC
- South Africa
- Egypt
- Rest of MEA
Need industry data? Please contact us today.
The report also includes profiles and for some of the leading companies in the Respiratory Drug Delivery Market, 2024 to 2034, with a focus on this segment of these companies’ operations.
Leading companies profiled in the report
- 3M
- AptarGroup Inc.
- AstraZeneca
- Boehringer Ingelheim International GmbH
- Cipla Inc.
- GF Health Products Inc.
- Glenmark Pharmaceuticals Ltd.
- GSK plc.
- Koninklijke Philips N.V.
- Medisana GmbH
- Merck & Co.
- Novartis AG
- Omron Corporation
- Recipharm AB
- Sumitomo Pharma Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
- Vapotherm
Overall world revenue for Respiratory Drug Delivery Market, 2024 to 2034 in terms of value the market will surpass US$67.0 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Respiratory Drug Delivery Market, 2024 to 2034 report help you?
In summary, our 340+ page report provides you with the following knowledge:
- Revenue forecasts to 2034 for Respiratory Drug Delivery Market, 2024 to 2034, with forecasts for product, formulations, devices, nebulizers, canister, application and end-users, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
- Revenue forecasts to 2034 for five regional and 25 key national markets – See forecasts for the Respiratory Drug Delivery Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, Spain, Switzerland, Russia, China, India, Japan, Australia, South Korea, South East Asia, Argentina, GCC, South Africa, and Egypt among other prominent economies.
- Prospects for established firms and those seeking to enter the market – including company profiles for 17 of the major companies involved in the Respiratory Drug Delivery Market, 2024 to 2034.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the respiratory drug delivery Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Respiratory Drug Delivery Market Report 2024-2034: Forecasts by Product (Formulations, Devices), by Formulations (Dry Powder, Suspension Aerosol, Solution Aerosol), by Devices (Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs), Nebulizers, Accessories), by Nebulizers (Soft Mist Nebulizers, Jet Nebulizers, Ultrasonic Nebulizers), by Canister (Plain Canisters, Coated Canister), by Application (Asthma, COPD, Cystic Fibrosis, Others), by End-users (Homecare Settings, Hospitals & Clinics, Other) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com
1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Respiratory Drug Delivery Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.2 Technological Advancements in Respiratory Drug Delivery Expected to Boost the Market
3.2.1.3 Outbreak of COVID-19 Pandemic
3.2.1.4 Growing Support of Government and NGOs for Respiratory Diseases Healthcare Awareness
3.2.1.5 Launch of Smart/Digital Inhalers will Propel the Adoption of Advanced Drug Delivery Devices
3.2.2 Market Restraining Factors
3.2.2.1 Stringent Government Regulations is Expected to Hinder the Market Growth
3.2.2.2 Intense Competition Among Vendors is Projected to Restrain the Market Growth
3.2.2.3 Pricing Pressure a Major Challenge
3.2.2.4 Challenges Associated with Respiratory Drugs Delivery Design
3.2.3 Market Opportunities
3.2.3.1 Trends in Metered Dose Inhaler (MDI) Technology is Expected to Propel the Market in Near Future
3.2.3.2 Mergers, Agreements, and Acquisitions by Market Players is a Major Trend Witnessed in the Market
3.2.3.3 Dry Powder Drug Delivery Product Innovation Driving the Adoption of Respiratory Drugs
3.2.3.4 Increase in Research and Development in Pulmonary Drug Delivery System
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Supplier: High
3.4.2 Threat of New Entrants: Moderate
3.4.3 Bargaining Power of Buyer: Moderate
3.4.4 Competitive Rivalry: High
3.4.5 Threat of Substitutes: Moderate
3.5 SWOT Analysis
3.6 PEST Analysis
3.6.1 Political Factors Impacting Respiratory Drug Delivery Market
3.6.2 Economic Factors Impacting Respiratory Drug Delivery Market
3.6.3 Social Factors Impacting Respiratory Drug Delivery Market
3.6.4 Technological Factors Impacting Respiratory Drug Delivery Market
4 Respiratory Drug Delivery Market Analysis by Product
4.1 Key Findings
4.2 Product Segment: Market Attractiveness Index
4.3 Respiratory Drug Delivery Market Size Estimation and Forecast by Product
4.4 Formulations
4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
4.4.2 Market Share by Region, 2024 & 2034 (%)
4.5 Devices
4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
4.5.2 Market Share by Region, 2024 & 2034 (%)
5 Respiratory Drug Delivery Market by Formulations
5.1 Key Findings
5.2 Formulations Segment: Market Attractiveness Index
5.3 Respiratory Drug Delivery Market, by Formulations
5.4 Dry Powder Formulation
5.4.1 Market Size by Region, 2024-2034 (US$ Billion)
5.4.2 Market Share by Region, 2024 & 2034 (%)
5.5 Suspension Aerosol
5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
5.5.2 Market Share by Region, 2024 & 2034 (%)
5.6 Solution Aerosol
5.6.1 Market Size by Region, 2024-2034 (US$ Billion)
5.6.2 Market Share by Region, 2024 & 2034 (%)
6 Respiratory Drug Delivery Market by Devices
6.1 Key Findings
6.2 Devices Segment: Market Attractiveness Index
6.3 Respiratory Drug Delivery Market Size Estimation and Forecast by Devices
6.4 Metered Dose Inhalers (MDIs)
6.4.1 Market Size by Region, 2024-2034 (US$ Billion)
6.4.2 Market Share by Region, 2024 & 2034 (%)
6.5 Dry Powder Inhalers (DPIs)
6.5.1 Market Size by Region, 2024-2034 (US$ Billion)
6.5.2 Market Share by Region, 2024 & 2034 (%)
6.6 Nebulizers
6.6.1 Market Size by Region, 2024-2034 (US$ Billion)
6.6.2 Market Share by Region, 2024 & 2034 (%)
6.7 Accessories
6.7.1 Market Size by Region, 2024-2034 (US$ Billion)
6.7.2 Market Share by Region, 2024 & 2034 (%)
7 Respiratory Drug Delivery Market by Nebulizers
7.1 Key Findings
7.2 Nebulizers Segment: Market Attractiveness Index
7.3 Respiratory Drug Delivery Market by Nebulizers Forecast, 2024-2034
7.4 Soft Mist Nebulizers
7.4.1 Market Size by Region, 2024-2034 (US$ Billion)
7.4.2 Market Share by Region, 2024 & 2034 (%)
7.5 Jet Nebulizers
7.5.1 Market Size by Region, 2024-2034 (US$ Billion)
7.5.2 Market Share by Region, 2024 & 2034 (%)
7.6 Ultrasonic Nebulizers
7.6.1 Market Size by Region, 2024-2034 (US$ Billion)
7.6.2 Market Share by Region, 2024 & 2034 (%)
8 Respiratory Drug Delivery Market by Canister
8.1 Key Findings
8.2 Canister Segment: Market Attractiveness Index
8.3 Respiratory Drug Delivery Market Size Estimation and Forecast by Canister
8.4 Plain canisters
8.4.1 Market Size by Region, 2024-2034 (US$ Billion)
8.4.2 Market Share by Region, 2024 & 2034 (%)
8.5 Coated canisters
8.5.1 Market Size by Region, 2024-2034 (US$ Billion)
8.5.2 Market Share by Region, 2024 & 2034 (%)
9 Respiratory Drug Delivery Market by Application
9.1 Key Findings
9.2 Application Segment: Market Attractiveness Index
9.3 Respiratory Drug Delivery Market Size Estimation and Forecast by Application
9.4 Asthma
9.4.1 Market Size by Region, 2024-2034 (US$ Billion)
9.4.2 Market Share by Region, 2024 & 2034 (%)
9.5 Chronic Obstructive Pulmonary Disease (COPD)
9.5.1 Market Size by Region, 2024-2034 (US$ Billion)
9.5.2 Market Share by Region, 2024 & 2034 (%)
9.6 Cystic Fibrosis
9.6.1 Market Size by Region, 2024-2034 (US$ Billion)
9.6.2 Market Share by Region, 2024 & 2034 (%)
9.7 Others
9.7.1 Market Size by Region, 2024-2034 (US$ Billion)
9.7.2 Market Share by Region, 2024 & 2034 (%)
10 Respiratory Drug Delivery Market by End-users
10.1 Key Findings
10.2 End-users Segment: Market Attractiveness Index
10.3 Respiratory Drug Delivery Market Size Estimation and Forecast by End-users
10.4 Homecare Settings
10.4.1 Market Size by Region, 2024-2034 (US$ Billion)
10.4.2 Market Share by Region, 2024 & 2034 (%)
10.5 Hospital & Clinics
10.5.1 Market Size by Region, 2024-2034 (US$ Billion)
10.5.2 Market Share by Region, 2024 & 2034 (%)
10.6 Other End-users
10.6.1 Market Size by Region, 2024-2034 (US$ Billion)
10.6.2 Market Share by Region, 2024 & 2034 (%)
11 Respiratory Drug Delivery Market Analysis by Region
11.1 Key Findings
11.2 Regional Market Size Estimation and Forecast
12 North America Respiratory Drug Delivery Market Analysis
12.1 Key Findings
12.2 North America Respiratory Drug Delivery Market Attractiveness Index
12.3 North America Respiratory Drug Delivery Market by Country, 2024, 2029 & 2034 (US$ Billion)
12.4 North America Respiratory Drug Delivery Market Size Estimation and Forecast by Country
12.5 North America Respiratory Drug Delivery Market Size Estimation and Forecast by Product
12.6 North America Respiratory Drug Delivery Market Size Estimation and Forecast by Formulation
12.7 North America Respiratory Drug Delivery Market Size Estimation and Forecast by Devices
12.8 North America Respiratory Drug Delivery Market Size Estimation and Forecast by Application
12.9 North America Respiratory Drug Delivery Market Size Estimation and Forecast by Canister
12.10 North America Respiratory Drug Delivery Market Size Estimation and Forecast by Nebulizers
12.11 North America Respiratory Drug Delivery Market Size Estimation and Forecast by End-users
12.12 U.S. Respiratory Drug Delivery Market Analysis
12.13 Canada Respiratory Drug Delivery Market Analysis
13 Europe Respiratory Drug Delivery Market Analysis
13.1 Key Findings
13.2 Europe Respiratory Drug Delivery Market Attractiveness Index
13.3 Europe Respiratory Drug Delivery Market by Country, 2024, 2029 & 2034 (US$ Billion)
13.4 Europe Respiratory Drug Delivery Market Size Estimation and Forecast by Country
13.5 Europe Respiratory Drug Delivery Market Size Estimation and Forecast by Product
13.6 Europe Respiratory Drug Delivery Market Size Estimation and Forecast by Formulation
13.7 Europe Respiratory Drug Delivery Market Size Estimation and Forecast by Devices
13.8 Europe Respiratory Drug Delivery Market Size Estimation and Forecast by Application
13.9 Europe Respiratory Drug Delivery Market Size Estimation and Forecast by Canister
13.10 Europe Respiratory Drug Delivery Market Size Estimation and Forecast by Nebulizers
13.11 Europe Respiratory Drug Delivery Market Size Estimation and Forecast by End-users
13.12 Germany Respiratory Drug Delivery Market Analysis
13.13 UK Respiratory Drug Delivery Market Analysis
13.14 France Respiratory Drug Delivery Market Analysis
13.15 Italy Respiratory Drug Delivery Market Analysis
13.16 Spain Respiratory Drug Delivery Market Analysis
13.17 Switzerland Respiratory Drug Delivery Market Analysis
13.18 Russia Respiratory Drug Delivery Market Analysis
13.19 Rest of Europe Respiratory Drug Delivery Market Analysis
14 Asia Pacific Respiratory Drug Delivery Market Analysis
14.1 Key Findings
14.2 Asia Pacific Respiratory Drug Delivery Market Attractiveness Index
14.3 Asia Pacific Respiratory Drug Delivery Market by Country, 2024, 2029 & 2034 (US$ Billion)
14.4 Asia Pacific Respiratory Drug Delivery Market Size Estimation and Forecast by Country
14.5 Asia Pacific Respiratory Drug Delivery Market Size Estimation and Forecast by Product
14.6 Asia Pacific Respiratory Drug Delivery Market Size Estimation and Forecast by Formulation
14.7 Asia Pacific Respiratory Drug Delivery Market Size Estimation and Forecast by Devices
14.8 Asia Pacific Respiratory Drug Delivery Market Size Estimation and Forecast by Application
14.9 Asia Pacific Respiratory Drug Delivery Market Size Estimation and Forecast by Canister
14.10 Asia Pacific Respiratory Drug Delivery Market Size Estimation and Forecast by Nebulizers
14.11 Asia Pacific Respiratory Drug Delivery Market Size Estimation and Forecast by End-users
14.12 Japan Respiratory Drug Delivery Market Analysis
14.13 China Respiratory Drug Delivery Market Analysis
14.14 India Respiratory Drug Delivery Market Analysis
14.15 Australia Respiratory Drug Delivery Market Analysis
14.16 South Korea Respiratory Drug Delivery Market Analysis
14.17 South East Asia Respiratory Drug Delivery Market Analysis
14.18 Rest of Asia Pacific Respiratory Drug Delivery Market Analysis
15 Latin America Respiratory Drug Delivery Market Analysis
15.1 Key Findings
15.2 Latin America Respiratory Drug Delivery Market Attractiveness Index
15.3 Latin America Respiratory Drug Delivery Market by Country, 2024, 2029 & 2034 (US$ Billion)
15.4 Latin America Respiratory Drug Delivery Market Size Estimation and Forecast by Country
15.5 Latin America Respiratory Drug Delivery Market Size Estimation and Forecast by Product
15.6 Latin America Respiratory Drug Delivery Market Size Estimation and Forecast by Formulation
15.7 Latin America Respiratory Drug Delivery Market Size Estimation and Forecast by Devices
15.8 Latin America Respiratory Drug Delivery Market Size Estimation and Forecast by Application
15.9 Latin America Respiratory Drug Delivery Market Size Estimation and Forecast by Canister
15.10 Latin America Respiratory Drug Delivery Market Size Estimation and Forecast by Nebulizers
15.11 Latin America Respiratory Drug Delivery Market Size Estimation and Forecast by End-users
15.12 Brazil Respiratory Drug Delivery Market Analysis
15.13 Mexico Respiratory Drug Delivery Market Analysis
15.14 Argentina Respiratory Drug Delivery Market Analysis
15.15 Rest of Latin America Respiratory Drug Delivery Market Analysis
16 MEA Respiratory Drug Delivery Market Analysis
16.1 Key Findings
16.2 MEA Respiratory Drug Delivery Market Attractiveness Index
16.3 MEA Respiratory Drug Delivery Market by Country, 2024, 2029 & 2034 (US$ Billion)
16.4 MEA Respiratory Drug Delivery Market Size Estimation and Forecast by Country
16.5 MEA Respiratory Drug Delivery Market Size Estimation and Forecast by Product
16.6 MEA Respiratory Drug Delivery Market Size Estimation and Forecast by Formulation
16.7 MEA Respiratory Drug Delivery Market Size Estimation and Forecast by Devices
16.8 MEA Respiratory Drug Delivery Market Size Estimation and Forecast by Application
16.9 MEA Respiratory Drug Delivery Market Size Estimation and Forecast by Canister
16.10 MEA Respiratory Drug Delivery Market Size Estimation and Forecast by Nebulizers
16.11 MEA Respiratory Drug Delivery Market Size Estimation and Forecast by End-users
16.12 GCC Respiratory Drug Delivery Market Analysis
16.13 South Africa Respiratory Drug Delivery Market Analysis
16.14 Egypt Respiratory Drug Delivery Market Analysis
16.15 Rest of MEA Respiratory Drug Delivery Market Analysis
17 Company Profiles
17.1 Competitive Landscape, 2022
17.2 GSK plc
17.2.1 Company Snapshot
17.2.2 Company Overview
17.2.3 Financial Analysis
17.2.3.1 Net Revenue, 2018-2022
17.2.3.2 R&D, 2018-2022
17.2.3.3 Regional Market Shares, 2022
17.2.4 Product Benchmarking
17.2.5 Strategic Outlook
17.3 Koninklijke Philips N.V.
17.3.1 Company Snapshot
17.3.2 Company Overview
17.3.3 Financial Analysis
17.3.3.1 Net Revenue, 2018-2022
17.3.3.2 R&D, 2018-2022
17.3.3.3 Segment Market Shares, 2022
17.3.3.4 Regional Market Shares, 2022
17.3.4 Product Benchmarking
17.3.5 Strategic Outlook
17.4 3M
17.4.1 Company Snapshot
17.4.2 Company Overview
17.4.3 Financial Analysis
17.4.3.1 Net Revenue, 2018-2022
17.4.3.2 R&D, 2018-2022
17.4.3.3 Segment Market Shares, 2022
17.4.3.4 Regional Market Shares, 2022
17.4.4 Product Benchmarking
17.4.5 Strategic Outlook
17.5 Boehringer Ingelheim International GmbH
17.5.1 Company Snapshot
17.5.2 Company Overview
17.5.3 Financial Analysis
17.5.3.1 Net Revenue, 2018-2022
17.5.3.2 Segment Market Shares, 2022
17.5.3.3 Regional Market Shares, 2022
17.5.4 Product Benchmarking
17.5.5 Strategic Outlook
17.6 AstraZeneca
17.6.1 Company Snapshot
17.6.2 Company Overview
17.6.3 Financial Analysis
17.6.3.1 Net Revenue, 2018-2022
17.6.3.2 R&D, 2018-2022
17.6.3.3 Segment Market Shares, 2022
17.6.3.4 Regional Market Shares, 2022
17.6.4 Product Benchmarking
17.6.5 Strategic Outlook
17.7 Merck & Co., Inc.
17.7.1 Company Snapshot
17.7.2 Company Overview
17.7.3 Financial Analysis
17.7.3.1 Net Revenue, 2018-2022
17.7.3.2 R&D, 2018-2022
17.7.3.3 Segment Market Shares, 2022
17.7.3.4 Regional Market Shares, 2022
17.7.4 Product Benchmarking
17.7.5 Strategic Outlook
17.8 Novartis AG
17.8.1 Company Snapshot
17.8.2 Company Overview
17.8.3 Financial Analysis
17.8.3.1 Net Revenue, 2018-2022
17.8.3.2 R&D, 2018-2022
17.8.3.3 Segment Market Shares, 2022
17.8.3.4 Regional Market Shares, 2022
17.8.4 Product Benchmarking
17.8.5 Strategic Outlook
17.9 Omron Corporation
17.9.1 Company Snapshot
17.9.2 Company Overview
17.9.3 Financial Analysis
17.9.3.1 Net Revenue, 2018-2022
17.9.3.2 R&D, 2018-2022
17.9.3.3 Segment Market Shares, 2022
17.9.3.4 Regional Market Shares, 2022
17.9.4 Product Benchmarking
17.9.5 Strategic Outlook
17.10 Sumitomo Pharma Co., Ltd.
17.10.1 Company Snapshot
17.10.2 Company Overview
17.10.3 Financial Analysis
17.10.3.1 Net Revenue, 2019-2023
17.10.3.2 R&D, 2019-2023
17.10.4 Product Benchmarking
17.10.5 Strategic Outlook
17.11 Teva Pharmaceutical Industries Ltd.
17.11.1 Company Snapshot
17.11.2 Company Overview
17.11.3 Financial Analysis
17.11.3.1 Net Revenue, 2018-2022
17.11.3.2 R&D, 2018-2022
17.11.3.3 Regional Market Shares, 2022
17.11.4 Product Benchmarking
17.11.5 Strategic Outlook
17.12 Cipla Inc.
17.12.1 Company Snapshot
17.12.2 Company Overview
17.12.3 Financial Analysis
17.12.3.1 Net Revenue, 2019-2023
17.12.3.2 Segment Market Shares, 2023
17.12.3.3 Regional Market Shares, 2023
17.12.4 Product Benchmarking
17.12.5 Strategic Outlook
17.13 Medisana GmbH
17.13.1 Company Snapshot
17.13.2 Company Overview
17.13.3 Product Benchmarking
17.14 GF Health Products, Inc.
17.14.1 Company Snapshot
17.14.2 Company Overview
17.14.3 Product Benchmarking
17.15 AptarGroup, Inc.
17.15.1 Company Snapshot
17.15.2 Company Overview
17.15.3 Financial Analysis
17.15.3.1 Net Revenue, 2018-2022
17.15.3.2 R&D, 2018-2022
17.15.3.3 Segment Market Shares, 2022
17.15.3.4 Regional Market Shares, 2022
17.15.4 Product Benchmarking
17.15.5 Strategic Outlook
17.16 Recipharm AB
17.16.1 Company Snapshot
17.16.2 Company Overview
17.16.3 Financial Analysis
17.16.3.1 Net Revenue, 2018-2022
17.16.4 Product Benchmarking
17.16.5 Strategic Outlook
17.17 Glenmark Pharmaceuticals Ltd.
17.17.1 Company Snapshot
17.17.2 Company Overview
17.17.3 Financial Analysis
17.17.3.1 Net Revenue, 2018-2022
17.17.3.2 Regional Market Shares, 2022
17.17.4 Product Benchmarking
17.18 Vapotherm, Inc.
17.18.1 Company Snapshot
17.18.2 Company Overview
17.18.3 Financial Analysis
17.18.3.1 Net Revenue, 2018-2022
17.18.3.2 R&D, 2018-2022
17.18.3.3 Segment Market Shares, 2022
17.18.3.4 Regional Market Shares, 2022
17.18.4 Product Benchmarking
17.18.5 Strategic Outlook
18 Conclusion and Recommendations
18.1 Concluding Remarks from Visiongain
18.2 Recommendations for Market Players
List of Tables
Table 1 Respiratory Drug Delivery Market Snapshot, 2024 & 2034 (US$ Billion, CAGR %)
Table 2 Respiratory Drug Delivery Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): “V” Shaped Recovery
Table 3 Respiratory Drug Delivery Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): “U” Shaped Recovery
Table 4 Respiratory Drug Delivery Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): “W” Shaped Recovery
Table 5 Respiratory Drug Delivery Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): “L” Shaped Recovery
Table 6 Respiratory Drug Delivery Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 7 Formulations Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 8 Devices Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 9 Respiratory Drug Delivery Market by Formulations, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 10 Dry Powder Formulation Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 11 Suspension aerosol Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 12 Solution Aerosol Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 13 Respiratory Drug Delivery Market Forecast by Devices, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 14 Metered Dose Inhaler (MDIs) Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 15 Dry Powder Inhalers (DPIs) Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 16 Nebulizers Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 17 Accessories Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 18 Respiratory Drug Delivery Market by Nebulizers, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 19 Soft Mist Nebulizers Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 20 Jet Nebulizers Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 21 Ultrasonic Nebulizers Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 22 Respiratory Drug Delivery Market Forecast by Canister, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 23 Plain canisters Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 24 Coated canisters Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 25 Respiratory Drug Delivery Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 26 Asthma Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 27 Chronic Obstructive Pulmonary Disease (COPD) Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 28 Cystic Fibrosis Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 29 Others Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 30 Respiratory Drug Delivery Market Forecast by End-users, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 31 Homecare Settings Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 32 Hospital & Clinics Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 33 Other End-users Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 34 Respiratory Drug Delivery Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 35 North America Respiratory Drug Delivery Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 36 North America Respiratory Drug Delivery Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 37 North America Respiratory Drug Delivery Market Forecast by Formulation, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 38 North America Respiratory Drug Delivery Market Forecast by Devices, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 39 North America Respiratory Drug Delivery Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 40 North America Respiratory Drug Delivery Market Forecast by Canister, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 41 North America Respiratory Drug Delivery Market Forecast by Nebulizers, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 42 North America Respiratory Drug Delivery Market Forecast by End-users, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 43 U.S. Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 44 Canada Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 45 Europe Respiratory Drug Delivery Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 46 Europe Respiratory Drug Delivery Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 47 Europe Respiratory Drug Delivery Market Forecast by Formulation, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 48 Europe Respiratory Drug Delivery Market Forecast by Devices, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 49 Europe Respiratory Drug Delivery Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 50 Europe Respiratory Drug Delivery Market Forecast by Canister, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 51 Europe Respiratory Drug Delivery Market Forecast by Nebulizers, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 52 Europe Respiratory Drug Delivery Market Forecast by End-users, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 53 Germany Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 54 UK Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 55 France Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 56 Italy Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 57 Spain Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 58 Switzerland Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 59 Russia Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 60 Rest of Europe Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 61 Asia Pacific Respiratory Drug Delivery Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 62 Asia Pacific Respiratory Drug Delivery Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 63 Asia Pacific Respiratory Drug Delivery Market Forecast by Formulation, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 64 Asia Pacific Respiratory Drug Delivery Market Forecast by Devices, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 65 Asia Pacific Respiratory Drug Delivery Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 66 Asia Pacific Respiratory Drug Delivery Market Forecast by Canister, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 67 Asia Pacific Respiratory Drug Delivery Market Forecast by Nebulizers, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 68 Asia Pacific Respiratory Drug Delivery Market Forecast by End-users, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 69 Japan Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 70 China Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 71 India Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 72 Australia Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 73 South Korea Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 74 South East Asia Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 75 Rest of Asia Pacific Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 76 Latin America Respiratory Drug Delivery Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 77 Latin America Respiratory Drug Delivery Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 78 Latin America Respiratory Drug Delivery Market Forecast by Formulation, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 79 Latin America Respiratory Drug Delivery Market Forecast by Devices, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 80 Latin America Respiratory Drug Delivery Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 81 Latin America Respiratory Drug Delivery Market Forecast by Canister, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 82 Latin America Respiratory Drug Delivery Market Forecast by Nebulizers, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 83 Latin America Respiratory Drug Delivery Market Forecast by End-users, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 84 Brazil Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 85 Mexico Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 86 Argentina Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 87 Rest of Latin America Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 88 MEA Respiratory Drug Delivery Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 89 MEA Respiratory Drug Delivery Market Forecast by Product, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 90 MEA Respiratory Drug Delivery Market Forecast by Formulation, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 91 MEA Respiratory Drug Delivery Market Forecast by Devices, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 92 MEA Respiratory Drug Delivery Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 93 MEA Respiratory Drug Delivery Market Forecast by Canister, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 94 MEA Respiratory Drug Delivery Market Forecast by Nebulizers, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 95 MEA Respiratory Drug Delivery Market Forecast by End-users, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 96 GCC Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 97 South Africa Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 98 Egypt Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 99 Rest of MEA Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 100 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 101 GSK plc: Product Benchmarking
Table 102 GSK plc: Strategic Outlook
Table 103 Koninklijke Philips N.V.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 104 Koninklijke Philips N.V.: Product Benchmarking
Table 105 Koninklijke Philips N.V.: Strategic Outlook
Table 106 3M: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 107 3M: Product Benchmarking
Table 108 3M: Strategic Outlook
Table 109 Boehringer Ingelheim International GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 110 Boehringer Ingelheim International GmbH: Product Benchmarking
Table 111 Boehringer Ingelheim International GmbH: Strategic Outlook
Table 112 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 113 AstraZeneca: Product Benchmarking
Table 114 AstraZeneca: Strategic Outlook
Table 115 Merck & Co., Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 116 Merck & Co., Inc.: Product Benchmarking
Table 117 Merck & Co., Inc.: Strategic Outlook
Table 118 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 119 Novartis AG: Product Benchmarking
Table 120 Novartis AG: Strategic Outlook
Table 121 Omron Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 122 Omron Corporation.: Product Benchmarking
Table 123 Omron Corporation.: Strategic Outlook
Table 124 Sumitomo Pharma Co., Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 125 Sumitomo Pharma Co., Ltd.: Product Benchmarking
Table 126 Sumitomo Pharma Co., Ltd.: Strategic Outlook
Table 127 Teva Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 128 Teva Pharmaceutical Industries Ltd.: Product Benchmarking
Table 129 Teva Pharmaceutical Industries Ltd.: Strategic Outlook
Table 130 Cipla Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 131 Cipla Inc.: Product Benchmarking
Table 132 Cipla Inc.: Strategic Outlook
Table 133 Medisana GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 134 Medisana GmbH: Product Benchmarking
Table 135 GF Health Products, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 136 GF Health Products, Inc.: Product Benchmarking
Table 137 AptarGroup, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 138 AptarGroup, Inc.: Product Benchmarking
Table 139 AptarGroup, Inc.: Strategic Outlook
Table 140 Recipharm AB: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 141 Recipharm AB: Product Benchmarking
Table 142 Recipharm AB: Strategic Outlook
Table 143 Glenmark Pharmaceuticals Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 144 Glenmark Pharmaceuticals Ltd.: Product Benchmarking
Table 145 Vapotherm, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 146 Vapotherm, Inc.: Product Benchmarking
Table 147 Vapotherm, Inc.: Strategic Outlook
List of Figures
Figure 1 Respiratory Drug Delivery Market Segmentation
Figure 2 Respiratory Drug Delivery Market Attractiveness Index by Region
Figure 3 Respiratory Drug Delivery Market by Product: Market Attractiveness Index
Figure 4 Respiratory Drug Delivery Market by Formulation: Market Attractiveness Index
Figure 5 Respiratory Drug Delivery Market by Devices: Market Attractiveness Index
Figure 6 Respiratory Drug Delivery Market by Application: Market Attractiveness Index
Figure 7 Respiratory Drug Delivery Market by Canister: Market Attractiveness Index
Figure 8 Respiratory Drug Delivery Market by Nebulizers: Market Attractiveness Index
Figure 9 Respiratory Drug Delivery Market by End-users: Market Attractiveness Index
Figure 10 Respiratory Drug Delivery Market: Market Dynamics
Figure 11 Hospital Discharge Rates for In-patients with Disease of Respiratory Systems, Per 100,000 Inhabitants by Country, 2021
Figure 12 Respiratory Drug Delivery Market by Region, 2024-2034 (US$ Billion, AGR %): “V” Shaped Recovery
Figure 13 Respiratory Drug Delivery Market by Region, 2024-2034 (US$ Billion, AGR %): “U” Shaped Recovery
Figure 14 Respiratory Drug Delivery Market by Region, 2024-2034 (US$ Billion, AGR %): “W” Shaped Recovery
Figure 15 Respiratory Drug Delivery Market by Region, 2024-2034 (US$ Billion, AGR %): “L” Shaped Recovery
Figure 16 Respiratory Drug Delivery Market: Porter’s Five Forces Analysis
Figure 17 Respiratory Drug Delivery Market: SWOT Analysis
Figure 18 Respiratory Drug Delivery Market: PEST Analysis
Figure 19 Respiratory Drug Delivery Market by Product: Market Attractiveness Index
Figure 20 Respiratory Drug Delivery Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
Figure 21 Respiratory Drug Delivery Market Share Forecast by Product, 2024, 2029, 2034 (%)
Figure 22 Formulations Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 23 Formulations Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 24 Devices Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 25 Devices Market Share Forecast by Region, 2024 & 2034 (%)
Figure 26 Respiratory Drug Delivery Market by Formulations: Market Attractiveness Index
Figure 27 Respiratory Drug Delivery Market by Type, 2024-2034 (US$ Billion)
Figure 28 Respiratory Drug Delivery Market Share Forecast by Formulations,2024, 2029, 2034 (%)
Figure 29 Dry Powder Formulation Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 30 Dry Powder Formulation Market Share Forecast by Region, 2024 & 2034 (%)
Figure 31 Suspension aerosol Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 32 Suspension aerosol Market Share Forecast by Region, 2024 & 2034 (%)
Figure 33 Solution Aerosol Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 34 Solution Aerosol Market Share Forecast by Region, 2024 & 2034 (%)
Figure 35 Respiratory Drug Delivery Market by Devices: Market Attractiveness Index
Figure 36 Respiratory Drug Delivery Market Forecast by Type, 2024-2034 (US$ Billion)
Figure 37 Respiratory Drug Delivery Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 38 Metered Dose Inhaler (MDIs) Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 39 Metered Dose Inhaler (MDIs) Market Share Forecast by Region, 2024 & 2034 (%)
Figure 40 Dry Powder Inhalers (DPIs) Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 41 Dry Powder Inhalers (DPIs) Market Share Forecast by Region, 2024 & 2034 (%)
Figure 42 Nebulizers Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 43 Nebulizers Market Share Forecast by Region, 2024 & 2034 (%)
Figure 44 Accessories Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 45 Accessories Market Share Forecast by Region, 2024 & 2034 (%)
Figure 46 Respiratory Drug Delivery Market by Nebulizers: Market Attractiveness Index
Figure 47 Respiratory Drug Delivery Market by Nebulizers, 2024-2034 (US$ Billion)
Figure 48 Respiratory Drug Delivery Market Share by Nebulizers, 2024, 2029, 2034 (%)
Figure 49 Soft Mist Nebulizers Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 50 Soft Mist Nebulizers Market Share Forecast by Region, 2024 & 2034 (%)
Figure 51 Jet Nebulizers Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 52 Jet Nebulizers Market Share Forecast by Region, 2024 & 2034 (%)
Figure 53 Ultrasonic Nebulizers Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 54 Ultrasonic Nebulizers Market Share Forecast by Region, 2024 & 2034 (%)
Figure 55 Respiratory Drug Delivery Market by Canister: Market Attractiveness Index
Figure 56 Respiratory Drug Delivery Market Forecast by Canister, 2024-2034 (US$ Billion)
Figure 57 Respiratory Drug Delivery Market Share Forecast by Canister, 2024, 2029, 2034 (%)
Figure 58 Plain canisters Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 59 Plain canisters Market Share Forecast by Region, 2024 & 2034 (%)
Figure 60 Coated canisters Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 61 Coated canisters Market Share Forecast by Region, 2024 & 2034 (%)
Figure 62 Respiratory Drug Delivery Market by Application: Market Attractiveness Index
Figure 63 Respiratory Drug Delivery Market Forecast by Application, 2024-2034 (US$ Billion)
Figure 64 Respiratory Drug Delivery Market Share Forecast by Application, 2024, 2029, 2034 (%)
Figure 65 Asthma Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 66 Asthma Market Share Forecast by Region, 2024 & 2034 (%)
Figure 67 Chronic Obstructive Pulmonary Disease (COPD) Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 68 Chronic Obstructive Pulmonary Disease (COPD) Market Share Forecast by Region, 2024 & 2034 (%)
Figure 69 Cystic Fibrosis Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 70 Cystic Fibrosis Market Share Forecast by Region, 2024 & 2034 (%)
Figure 71 Others Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 72 Others Market Share Forecast by Region, 2024 & 2034 (%)
Figure 73 Respiratory Drug Delivery Market by End-users: Market Attractiveness Index
Figure 74 Respiratory Drug Delivery Market Forecast by End-users, 2024-2034 (US$ Billion)
Figure 75 Respiratory Drug Delivery Market Share Forecast by End-users, 2024, 2029, 2034 (%)
Figure 76 Homecare Settings Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 77 Homecare Settings Market Share Forecast by Region, 2024 & 2034 (%)
Figure 78 Hospital & Clinics Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 79 Hospital & Clinics Market Share Forecast by Region, 2024 & 2034 (%)
Figure 80 Other End-users Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 81 Others Market Share Forecast by Region, 2024 & 2034 (%)
Figure 82 Respiratory Drug Delivery Market Forecast by Region 2024 and 2034 (Revenue, CAGR%)
Figure 83 Respiratory Drug Delivery Market Share Forecast by Region 2024, 2029, 2034 (%)
Figure 84 Respiratory Drug Delivery Market by Region, 2024-2034 (US$ Billion, AGR %)
Figure 85 North America Respiratory Drug Delivery Market Attractiveness Index
Figure 86 North America Respiratory Drug Delivery Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 87 North America Respiratory Drug Delivery Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 88 North America Respiratory Drug Delivery Market Share Forecast by Country, 2024 & 2034 (%)
Figure 89 North America Respiratory Drug Delivery Market Forecast by Product, 2024-2034 (US$ Billion, AGR %)
Figure 90 North America Respiratory Drug Delivery Market Share Forecast by Product, 2024 & 2034 (%)
Figure 91 North America Respiratory Drug Delivery Market Forecast by Formulation, 2024-2034 (US$ Billion, AGR %)
Figure 92 North America Respiratory Drug Delivery Market Share Forecast by Formulation, 2024 & 2034 (%)
Figure 93 North America Respiratory Drug Delivery Market Forecast by Devices, 2024-2034 (US$ Billion, AGR %)
Figure 94 North America Respiratory Drug Delivery Market Share Forecast by Devices, 2024 & 2034 (%)
Figure 95 North America Respiratory Drug Delivery Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
Figure 96 North America Respiratory Drug Delivery Market Share Forecast by Application, 2024 & 2034 (%)
Figure 97 North America Respiratory Drug Delivery Market Forecast by Canister, 2024-2034 (US$ Billion, AGR %)
Figure 98 North America Respiratory Drug Delivery Market Share Forecast by Canister, 2024 & 2034 (%)
Figure 99 North America Respiratory Drug Delivery Market Forecast by Nebulizers, 2024-2034 (US$ Billion, AGR %)
Figure 100 North America Respiratory Drug Delivery Market Share Forecast by Nebulizers, 2024 & 2034 (%)
Figure 101 North America Respiratory Drug Delivery Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %)
Figure 102 North America Respiratory Drug Delivery Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 103 U.S. Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 104 Canada Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 105 Europe Respiratory Drug Delivery Market Attractiveness Index
Figure 106 Europe Respiratory Drug Delivery Market by Country, 2024, 2029 & 2034 (US$ Billion)
Figure 107 Europe Respiratory Drug Delivery Market Forecast by Country, 2024-2034 (US$ Billion)
Figure 108 Europe Respiratory Drug Delivery Market Share Forecast by Country, 2024 & 2034 (%)
Figure 109 Europe Respiratory Drug Delivery Market Forecast by Product, 2024-2034 (US$ Billion)
Figure 110 Europe Respiratory Drug Delivery Market Share Forecast by Product, 2024 & 2034 (%)
Figure 111 Europe Respiratory Drug Delivery Market Forecast by Formulation, 2024-2034 (US$ Billion)
Figure 112 Europe Respiratory Drug Delivery Market Share Forecast by Formulation, 2024 & 2034 (%)
Figure 113 Europe Respiratory Drug Delivery Market Forecast by Devices, 2024-2034 (US$ Billion)
Figure 114 Europe Respiratory Drug Delivery Market Share Forecast by Devices, 2024 & 2034 (%)
Figure 115 Europe Respiratory Drug Delivery Market Forecast by Application, 2024-2034 (US$ Billion)
Figure 116 Europe Respiratory Drug Delivery Market Share Forecast by Application, 2024 & 2034(%)
Figure 117 Europe Respiratory Drug Delivery Market Forecast by Canister, 2024-2034 (US$ Billion)
Figure 118 Europe Respiratory Drug Delivery Market Share Forecast by Canister, 2024 & 2034(%)
Figure 119 Europe Respiratory Drug Delivery Market Forecast by Nebulizers, 2024-2034 (US$ Billion)
Figure 120 Europe Respiratory Drug Delivery Market Share Forecast by Nebulizers, 2024 & 2034(%)
Figure 121 Europe Respiratory Drug Delivery Market Forecast by End-users, 2024-2034 (US$ Billion)
Figure 122 Europe Respiratory Drug Delivery Market Share Forecast by End-users, 2024 & 2034(%)
Figure 123 Germany Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 124 UK Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 125 France Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 126 Italy Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 127 Spain Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 128 Switzerland Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 129 Russia Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 130 Rest of Europe Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 131 Asia Pacific Respiratory Drug Delivery Market Attractiveness Index
Figure 132 Asia Pacific Respiratory Drug Delivery Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 133 Asia Pacific Respiratory Drug Delivery Market Forecast by Country, 2024-2034 (US$ Billion)
Figure 134 Asia Pacific Respiratory Drug Delivery Market Share Forecast by Country, 2024 & 2034 (%)
Figure 135 Asia Pacific Respiratory Drug Delivery Market Forecast by Product, 2024-2034 (US$ Billion)
Figure 136 Asia Pacific Respiratory Drug Delivery Market Share Forecast by Product, 2024 & 2034 (%)
Figure 137 Asia Pacific Respiratory Drug Delivery Market Forecast by Formulation, 2024-2034 (US$ Billion)
Figure 138 Asia Pacific Respiratory Drug Delivery Market Share Forecast by Formulation, 2024 & 2034 (%)
Figure 139 Asia Pacific Respiratory Drug Delivery Market Forecast by Devices, 2024-2034 (US$ Billion)
Figure 140 Asia Pacific Respiratory Drug Delivery Market Share Forecast by Devices, 2024 & 2034 (%)
Figure 141 Asia Pacific Respiratory Drug Delivery Market Forecast by Application, 2024-2034 (US$ Billion)
Figure 142 Asia Pacific Respiratory Drug Delivery Market Share Forecast by Application, 2024 & 2034 (%)
Figure 143 Asia Pacific Respiratory Drug Delivery Market Forecast by Canister, 2024-2034 (US$ Billion)
Figure 144 Asia Pacific Respiratory Drug Delivery Market Share Forecast by Canister, 2024 & 2034 (%)
Figure 145 Asia Pacific Respiratory Drug Delivery Market Forecast by Nebulizers, 2024-2034 (US$ Billion)
Figure 146 Asia Pacific Respiratory Drug Delivery Market Share Forecast by Nebulizers, 2024 & 2034 (%)
Figure 147 Asia Pacific Respiratory Drug Delivery Market Forecast by End-users, 2024-2034 (US$ Billion)
Figure 148 Asia Pacific Respiratory Drug Delivery Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 149 Japan Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 150 China Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 151 India Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 152 Australia Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 153 South Korea Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 154 South East Asia Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 155 Rest of Asia Pacific Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 156 Latin America Respiratory Drug Delivery Market Attractiveness Index
Figure 157 Latin America Respiratory Drug Delivery Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 158 Latin America Respiratory Drug Delivery Market Forecast by Country, 2024-2034 (US$ Billion)
Figure 159 Latin America Respiratory Drug Delivery Market Share Forecast by Country, 2024 & 2034 (%)
Figure 160 Latin America Respiratory Drug Delivery Market Forecast by Product, 2024-2034 (US$ Billion)
Figure 161 Latin America Respiratory Drug Delivery Market Share Forecast by Product, 2024 & 2034 (%)
Figure 162 Latin America Respiratory Drug Delivery Market Forecast by Formulation, 2024-2034 (US$ Billion)
Figure 163 Latin America Respiratory Drug Delivery Market Share Forecast by Formulation, 2024 & 2034 (%)
Figure 164 Latin America Respiratory Drug Delivery Market Forecast by Devices, 2024-2034 (US$ Billion)
Figure 165 Latin America Respiratory Drug Delivery Market Share Forecast by Devices, 2024 & 2034 (%)
Figure 166 Latin America Respiratory Drug Delivery Market Forecast by Application, 2024-2034 (US$ Billion)
Figure 167 Latin America Respiratory Drug Delivery Market Share Forecast by Application, 2024 & 2034 (%)
Figure 168 Latin America Respiratory Drug Delivery Market Forecast by Canister, 2024-2034 (US$ Billion)
Figure 169 Latin America Respiratory Drug Delivery Market Share Forecast by Canister, 2024 & 2034 (%)
Figure 170 Latin America Respiratory Drug Delivery Market Forecast by Nebulizers, 2024-2034 (US$ Billion)
Figure 171 Latin America Respiratory Drug Delivery Market Share Forecast by Nebulizers, 2024 & 2034 (%)
Figure 172 Latin America Respiratory Drug Delivery Market Forecast by End-users, 2024-2034 (US$ Billion)
Figure 173 Latin America Respiratory Drug Delivery Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 174 Brazil Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 175 Mexico Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 176 Argentina Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 177 Rest of Latin America Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 178 MEA Respiratory Drug Delivery Market Attractiveness Index
Figure 179 MEA Respiratory Drug Delivery Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 180 MEA Respiratory Drug Delivery Market Forecast by Country, 2024-2034 (US$ Billion)
Figure 181 MEA Respiratory Drug Delivery Market Share Forecast by Country, 2024 & 2034 (%)
Figure 182 MEA Respiratory Drug Delivery Market Forecast by Product, 2024-2034 (US$ Billion)
Figure 183 MEA Respiratory Drug Delivery Market Share Forecast by Product, 2024 & 2034 (%)
Figure 184 MEA Respiratory Drug Delivery Market Forecast by Formulation, 2024-2034 (US$ Billion)
Figure 185 MEA Respiratory Drug Delivery Market Share Forecast by Formulation, 2024 & 2034 (%)
Figure 186 MEA Respiratory Drug Delivery Market Forecast by Devices, 2024-2034 (US$ Billion)
Figure 187 MEA Respiratory Drug Delivery Market Share Forecast by Devices, 2024 & 2034 (%)
Figure 188 MEA Respiratory Drug Delivery Market Forecast by Application, 2024-2034 (US$ Billion)
Figure 189 MEA Respiratory Drug Delivery Market Share Forecast by Application, 2024 & 2034 (%)
Figure 190 MEA Respiratory Drug Delivery Market Forecast by Canister, 2024-2034 (US$ Billion)
Figure 191 MEA Respiratory Drug Delivery Market Share Forecast by Canister, 2024 & 2034 (%)
Figure 192 MEA Respiratory Drug Delivery Market Forecast by Nebulizers, 2024-2034 (US$ Billion)
Figure 193 MEA Respiratory Drug Delivery Market Share Forecast by Nebulizers, 2024 & 2034 (%)
Figure 194 MEA Respiratory Drug Delivery Market Forecast by End-users, 2024-2034 (US$ Billion)
Figure 195 MEA Respiratory Drug Delivery Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 196 GCC Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 197 South Africa Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 198 Egypt Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 199 Rest of MEA Respiratory Drug Delivery Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 200 Respiratory Drug Delivery Market: Company Share/Ranking, 2022
Figure 201 GSK plc: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 202 GSK plc: R&D, 2018-2022 (US$ Million, AGR %)
Figure 203 GSK plc: Regional Market Shares, 2022
Figure 204 Koninklijke Philips N.V.: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 205 Koninklijke Philips N.V.: R&D, 2018-2022 (US$ Million, AGR %)
Figure 206 Koninklijke Philips N.V.: Segment Market Shares, 2022
Figure 207 Koninklijke Philips N.V.: Regional Market Shares, 2022
Figure 208 3M: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 209 3M: R&D, 2018-2022 (US$ Million, AGR %)
Figure 210 3M: Segment Market Shares, 2022
Figure 211 3M: Regional Market Shares, 2022
Figure 212 Boehringer Ingelheim International GmbH: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 213 Boehringer Ingelheim International GmbH: Segment Market Shares, 2022
Figure 214 Boehringer Ingelheim International GmbH: Regional Market Shares, 2022
Figure 215 AstraZeneca: Net Revenue, 2018-2022 (US$ Million, AGR (%)
Figure 216 AstraZeneca: R&D, 2018-2022 (US$ Million, AGR %)
Figure 217 AstraZeneca: Segment Market Shares, 2022
Figure 218 AstraZeneca: Regional Market Shares, 2022
Figure 219 Merck & Co., Inc.: Net Revenue, 2018-2022 (US$ Million, AGR (%)
Figure 220 Merck & Co., Inc.: R&D, 2018-2022 (US$ Million, AGR %)
Figure 221 Merck & Co., Inc.: Segment Market Shares, 2022
Figure 222 Merck & Co., Inc.: Regional Market Shares, 2022
Figure 223 Novartis AG: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 224 Novartis AG: R&D, 2018-2022 (US$ Million, AGR %)
Figure 225 Novartis AG: Segment Market Shares, 2022
Figure 226 Novartis AG: Regional Market Shares, 2022
Figure 227 Omron Corporation: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 228 Omron Corporation: R&D, 2018-2022 (US$ Million, AGR %)
Figure 229 Omron Corporation: Segment Market Shares, 2022
Figure 230 Omron Corporation: Regional Market Shares, 2022
Figure 231 Sumitomo Pharma Co., Ltd.: Net Revenue, 2019-2023 (US$ Million, AGR %)
Figure 232 Sumitomo Pharma Co., Ltd.: R&D, 2019-2023 (US$ Million, AGR %)
Figure 233 Teva Pharmaceutical Industries Ltd.: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 234 Teva Pharmaceutical Industries Ltd.: R&D, 2018-2022 (US$ Million, AGR %)
Figure 235 Teva Pharmaceutical Industries Ltd.: Regional Market Shares, 2022
Figure 236 Cipla Inc.: Net Revenue, 2019-2023 (US$ Million, AGR %)
Figure 237 Cipla Inc.: Segment Market Shares, 2023
Figure 238 Cipla Inc.: Regional Market Shares, 2023
Figure 239 AptarGroup, Inc.: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 240 AptarGroup, Inc.: R&D, 2018-2022 (US$ Million, AGR %)
Figure 241 AptarGroup, Inc.: Segment Market Shares, 2022
Figure 242 AptarGroup, Inc.: Regional Market Shares, 2022
Figure 243 Recipharm AB: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 244 Glenmark Pharmaceuticals Ltd.: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 245 Glenmark Pharmaceuticals Ltd.: Regional Market Shares, 2022
Figure 246 Vapotherm, Inc.: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 247 Vapotherm, Inc.: R&D, 2018-2022 (US$ Million, AGR %)
Figure 248 Vapotherm, Inc.: Segment Market Shares, 2022
Figure 249 Vapotherm, Inc.: Regional Market Shares, 2022
List of Companies Profiled in the Report
3M
AptarGroup Inc.
AstraZeneca
Boehringer Ingelheim International GmbH
Cipla Inc.
GF Health Products Inc.
Glenmark Pharmaceuticals Ltd.
GSK plc.
Koninklijke Philips N.V.
Medisana GmbH
Merck & Co.
Novartis AG
Omron Corporation
Recipharm AB
Sumitomo Pharma Co., Ltd.
Teva Pharmaceutical Industries Ltd.
Vapotherm
List of Other Companies Mentioned in the Report
Accelerate Diagnostics
ADMENTA Italia Group
AeroRx Therapeutics
AeroRx Therapeutics
Aesica Pharmaceuticals Limited
Ahead Therapeutics
Anakuria Therapeutics, Inc.
Ark Biopharmaceutical Co., Ltd.
Arranta Bio
Aseptika
Aurigene Pharmaceutical Services
Avillion
Axios Health Education Services
CerTest Biotec
Chiesi Pharmaceuticals
Cohero Health
CS Pharmaceuticals
Daewoong Pharmaceutical
Dyadic International, Inc.
Ethris GmbH
Farmindustria
Generic Health Pty Ltd.
Genfa Global
GenIbet
Gilbert Technologies
HCmed Innovations
Honeywell
ID Pharma Co., Ltd.
Ikaria Australia Pty Ltd (Australia)
Inogen, Inc.
Ivera Medical Corp.
Janssen Biotech, Inc.
Kindeva
Lupin
m8 Pharmaceuticals
Magnolia Medical Technologies
Mallinckrodt International Holdings Sarl. (Luxemburg)
Moderna
Moderna, Inc.
Parata Systems
Pfizer
Pharmaron Beijing Co., Limited
Pulmonx Corporation
Regeneron
Remix Therapeutics
Respironics, Inc.
Rimidi
RYAH Group, Inc.
Sanofi Aventis Group
Scanwell Health, Inc.
Starpharma
Stevanato Group S.p.A.
Tepha, Inc
TFF Pharmaceuticals Inc.
Transpire Bio
Treo Solutions LLC
UCB Mexico
Uniphar Durbin Ireland Ltd.
VantAI
Vectura Plc
Venclose, Inc.
Vertex Pharmaceuticals
Viatris
WuXi
List of Organizations Mentioned in the Report
Asthma and Allergy Foundation of America (AAFA)
CAPA (Central Administration of Pharmaceutical Affairs)
Desert Oasis Healthcare (DOHC)
Egyptian Drug Authority (EDA)
Government of Canada
International Diabetes Federation (IDF)
Lee Kong Chian School of Medicine (LKCMedicine)
Liverpool School of Tropical Medicine
Local Commissions on Health and Family Planning
London's Imperial College
MHLW (Ministry of Health, Labour and Welfare)
Nanyang Technological University, Singapore (NTU Singapore)
National Commission on Health and Family Planning
National Health Service (NHS)
National Medical Products Administration (NMPA)
NODCAR (National Organisation for Drug Control and Research)
NORCB (National Organisation for Research and Control of Biologicals)
PMDA (Pharmaceuticals and Medical Devices Agency)
Royal College of Art.
Russian Medical Research Company
The Canadian Institutes for Health Research (CIHR)
The Central Drugs Standard Control Organisation (CDSCO)
The MHRA (Medicines and Healthcare Products Regulatory Agency)
The Therapeutic Goods Administration (TGA)
U.S. Department of Defence
U.S. FDA
UK National James Dyson
University of Liverpool
World Health Organization (WHO)
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
